Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes

被引:150
|
作者
Petroff, MGV
Egan, JM
Wang, XL
Sollott, SJ
机构
[1] NIA, Cardiovasc Sci Lab, Gerontol Res Ctr, Intramural Res Program,NIH, Baltimore, MD 21224 USA
[2] NIA, Diabet Sect, Gerontol Res Ctr, Intramural Res Program,NIH, Baltimore, MD 21224 USA
[3] Univ Nacl La Plata, Fac Ciencias Med, Ctr Invest Cardiovasc, La Plata, Buenos Aires, Argentina
关键词
cardiac myocytes; glucagon-like peptide-1; cAMP; calcium;
D O I
10.1161/hh1701.095716
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The gut hormone, glucagon-like peptide-1 (GLP-1), which is secreted in nanomolar amounts in response to nutrients in the intestinal lumen, exerts cAMP/protein kinase A-mediated insulinotropic actions in target endocrine tissues, but its actions in heart cells are unknown. GLP-1 (10 nmol/L) increased intracellular cAMP (from 5.7+/-0.5 to 13.1 +/- 0.12 pmol/mg protein) in rat cardiac myocytes. The effects of cAMP-doubling concentrations of both GLP-1 and isoproterenol (ISO. 10 nmol/L) on contraction amplitude, intracellular Ca2+ transient (CaT), and pH(i) in indo-1 and seminaphthorhodafluor (SNARF)-1 loaded myocytes were compared. Whereas ISO caused a characteristic increase (above baseline) in contraction amplitude (160+/-34%) and CaT (70+/-5%), GLP-1 induced a significant decrease in contraction amplitude (-27+/-5%) with no change in the CaT after 20 minutes. Neither pertussis toxin treatment nor exposure to the cGMP-stimulated phosphodiesterase (PDE2) inhibitor erythro-9-(2-hydroxy-3-nonyl)adenine or the nonselective PDE inhibitor 3-isobutyl-1-methylxanthine nor the phosphatase inhibitors okadaic acid or calyculin A unmasked an ISO-mimicking response of GLP-1. In SNARF-1-loaded myocytes, however, both ISO and GLP-1 caused an intracellular acidosis (Delta pH(i) -0.09+/-0.02 and -0.08+/-0.03, respectively). The specific GLP-1 antagonist exendin 9-39 and the cAMP inhibitory analog Rp-8CPT-cAMPS inhibited both the GLP-1-induced intracellular acidosis and the negative contractile effect. We conclude that in contrast to beta -adrenergic signaling, GLP-1 increases cAMP but fails to augment contraction, suggesting the existence of functionally distinct adenylyl cyclase/cAMP/protein kinase A compartments, possibly determined by unique receptor signaling microdomains that are not controlled by pertussis toxin-sensitive G proteins or by enhanced local PDE or phosphatase activation. Furthermore, GLP-1 elicits a cAMP-dependent modest negative inotropic effect produced by a decrease in myofilament-Ca2+ responsiveness probably resulting from intracellular acidification.
引用
收藏
页码:445 / 452
页数:8
相关论文
共 50 条
  • [1] Glucagon and glucagon-like peptide-1
    Livingston, JN
    Schoen, WR
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 34, 1999, 34 : 189 - 198
  • [2] Glucagon-like peptide-1
    Doyle, ME
    Egan, JM
    RECENT PROGRESS IN HORMONE RESEARCH, VOL 56, 2001, 56 : 377 - 399
  • [3] Glucagon-like peptide-1 and glucagon-like peptide-2
    Baggio, LL
    Drucker, DJ
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 18 (04) : 531 - 554
  • [4] GLUCAGON-LIKE PEPTIDE-1 IS A PHYSIOLOGICAL INCRETIN IN RAT
    WANG, ZL
    WANG, RM
    OWJI, AA
    SMITH, DM
    GHATEI, MA
    BLOOM, SR
    JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (01): : 417 - 421
  • [5] Glucagon-like peptide-1 and satiety
    S. R. Bloom
    Nature, 1997, 385 : 214 - 214
  • [6] Glucagon-Like Peptide-1 and Diabetes
    Monami, Matteo
    EXPERIMENTAL DIABETES RESEARCH, 2011,
  • [7] Glucagon-like peptide-1 and satiety
    G. van Dijk
    T. E. Thiele
    R. J. Seeley
    S. C. Woods
    I. L. Bernstein
    Nature, 1997, 385 : 214 - 214
  • [8] Glucagon-like peptide-1 and satiety
    van, Dijk, G.
    Thiele, T.E.
    Seeley, R.J.
    Woods, S.C.
    Bernstein, I.L.
    Bloom, S.R.
    Nature, 1997, 385 (6613)
  • [9] Glucagon-like peptide-1 receptor
    Krashes, Michael
    CURRENT BIOLOGY, 2024, 34 (23) : R1163 - R1164
  • [10] Is Glucagon-like peptide-1 for real?
    Murr, Michel M.
    SURGERY FOR OBESITY AND RELATED DISEASES, 2014, 10 (05) : 786 - 786